ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?
IceCure Medical Ltd. (ICCM) shares surged over 200% on Wednesday due to increased adoption of its ProSense system for breast cancer treatment. The company reported a 70% increase in U.S. commercial installations since FDA approval in October 2025. CEO Eyal Shamir cited growing physician interest and clinical acceptance. The stock is on track for its best day since August 2021. All three analysts covering ICCM rate it 'Buy' or higher, with an average price target of $44.50, implying a potential u
How this was made
The 30-second read
Why it matters
The reported install base expansion suggests early commercial traction, but the company still reports quarterly losses.
Market read
A micro‑cap biotech sees a sharp price surge on new adoption data, indicating short‑term trading interest but long‑term risk remains.
What to watch
Regulatory scrutiny on long‑term outcomes and reimbursement policies could temper growth.
Background
IceCure Medical's ProSense system received FDA clearance in Oct 2025 and is the only device approved for low‑risk breast cancer in women 70+.
Ticker impact
IceCure Medical reported a 70% increase in its U.S. ProSense install base, driving a >200% stock rally on Wednesday.
Further upside if install growth continues; watch for volatility on new guidance.
Rapid install growth signals market traction, but the company remains early‑stage and earnings are still negative.
Market effects
Highlights growing demand for minimally invasive breast cancer treatments, potentially benefiting other cryoablation device makers.
U.S. medical device market sees incremental demand from aging breast cancer patients.
Limited to niche oncology segment; broader market impact minimal.
Counterpoint
The rally may be speculative; without profitability and with high cash burn, the stock could face a pull‑back.
Key entities
- CompanyIceCure Medical Ltd.
Developer of the ProSense cryoablation system.
- ExecutiveEyal Shamir
CEO of IceCure Medical.
